Plasma Drug Concentration Time Profile Plotting Data

Similar documents
Nursing 113. Pharmacology Principles

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Course Curriculum for Master Degree in Clinical Pharmacy

IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.

Medication Utilization. Understanding Potential Medication Problems of the Elderly

Analytical Specifications RIVAROXABAN

Guidance for Industry

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM

PHAR 7633 Chapter 19 Multi-Compartment Pharmacokinetic Models

Statistics and Pharmacokinetics in Clinical Pharmacology Studies

NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997

BIOAVAILABILITY & BIOEQUIVALENCE TRIALS

Guidance for Industry Safety Testing of Drug Metabolites

Pharmacology skills for drug discovery. Why is pharmacology important?

Absorption of Drugs. Transport of a drug from the GI tract

A Peak at PK An Introduction to Pharmacokinetics

Food, Medicine and Health Care Administration and Control Authority

Masters Learning mode (Форма обучения)

Designing a Pharmacology Course for a Doctor of Physical Therapy Program

Biological importance of metabolites. Safety and efficacy aspects

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8

Clinical Study Synopsis for Public Disclosure

DOSE-EFFECT RELATIONSHIP

How To Remove A Drug By Therapeutic Apheresis

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Guidance for Industry

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

NIMULID MD. 1. Introduction. 2. Nimulid MD Drug delivery system

Understanding Our Curriculum

Decentralised Procedure. Public Assessment Report

Bioequivalence Study Design Considerations. Dr. John Gordon

Graduate Program in Pharmacology and Toxicology Bob Speth, Chair. Department of Pharmacology School of Pharmacy University of Mississippi

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more:

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

Clinical Study Synopsis

1: CLINICAL PHARMACOKINETICS

Guidance for Industry

ICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)

M4E(R2): The CTD Efficacy

Introduction to Enteris BioPharma

Session 6 Clinical Trial Assessment Phase I Clinical Trial

REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed])

Accreditation of Master of Pharmacy Degrees

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

CTC Technology Readiness Levels

4.1 Objectives of Clinical Trial Assessment

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1

Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA

PHAR 7633 Chapter 21 Non-Linear Pharmacokinetic Models

Guidance for Industry

PRINCIPLES OF PHARMACOLOGY. MEDICAL ASSISTANT S ROLE History: Drug Legislation & Regulation. Education: indication, instructions, side effects

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

Fexinidazole a new oral treatment for sleeping sickness update of development

Humulin (LY041001) Page 1 of 1

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

A FDA Perspective on Nanomedicine Current Initiatives in the US

Diabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Pharmaceutical Sciences

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE M3(R2)

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa

Drug Development Process

DIVISION OF HUMAN NUTRITION

DMPK: Experimentation & Data

Carl Rosow, M.D., Ph.D. 1 HST-151. Lecture 1 - Principles of Pharmacology: Introduction

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

Current version dated 5 March 2012

Guidance for Industry

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

5.5 Pharmacokinetics - Sublingual

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

Office of Clinical Standards and Quality / Survey & Certification Group

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

North-West University. School of Pharmacy. Short Courses: Introductory Guide

Clinical Trial Results Database Page 1

GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS

Classification for Drug related problems

From Drug Discovery to First in Humans

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Order Phenytoin dilantin ivpb rate when to order phenytoin level dilantin 30 mg

Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998

Guidance for Industry

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR

Basic Overview of Preclinical Toxicology Animal Models

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

Overview of Dissolution for BA/BE

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

BIOTECHNOLOGY OPERATIONS

Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain

Guidance for Industry

Graduate Program Objective #1 Course Objectives

Pharmacy Technician Syllabus 14152

Overview of Drug Development: the Regulatory Process

Journal of Chemical and Pharmaceutical Research

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Transcription:

UNIT 2 PHARMACOKINETICS-BASIC CONSIDERATIONS Plasma Drug Concentration Time Profile Plotting Data S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University

INTRODUCTION TO PHARMACOKINETICS The duration of a drug therapy ranges from a single dose of a drug taken for relieving an acute condition such as headache to drugs taken life long for chronic conditions such as hypertension, diabetes, asthma or epilepsy. The frequency of administration of a drug in a particular dose is called as Dosage regimen. Depending upon the therapeutic objective to be attained, the duration of drug therapy and the dosage regimen are decided.

Rational and optimal therapy with a drug depend upon 1. Choice of a suitable drug, and 2. Balance between the therapeutic and the toxiceffects. Both, the therapeutic and the toxic effects, depend upon the concentration of drug at the site of action which is difficult to measure. However, it corresponds to a specific concentration of drug in plasma which can be measured with accuracy. The drug fails to elicit a therapeutic response when the concentration is below the effective level and precipitates adverse reactions when above the toxic level. The plasma drug concentration between these two limits is called as the Therapeutic concentration range or Therapeutic window.

The ratio of maximum safe concentration to minimum effective concentration of the drug is called as the Therapeutic index. Thus, in order to achieve therapeutic success, plasma concentration of the drug should be maintained within the therapeutic window. For this, knowledge is needed not only of the mechanisms of drug absorption, distribution, metabolism and excretion, but also of the kinetics of these processes i.e. Pharmacokinetics.

Definitions Pharmacokinetics is defined as the kinetics of drug absorption, distribution, metabolism and excretion (KADME) and their relationship with the pharmacological, therapeutic or toxicological response in humans. Absorption is defined as the process of movement of unchanged drug from the site of administration to systemic circulation (or to the site of measurement i.e. plasma). Distribution is reversible transfer of a drug between the blood and the extra vascular fluids and tissues.

Elimination is the major process for removal of a drug from the body and termination of its action. It is defined as the irreversible loss of drug from the body. Elimination occurs by two processes viz. biotransformation and excretion. Metabolism (Biotransformation) of drugs is defined as the chemical conversion of one form to another. Excretion is defined as the process whereby drugs and/or their metabolites are irreversibly transferred from internal to external environment.

Pharmacokinetic Studies There are two aspects of pharmacokinetic studies 1.Theoretical aspect: which involves development of pharmacokinetic models to predict drug disposition after its administration. Statistical methods are commonly applied to interpret data and assess various parameters. 2. Experimental aspect: which involves development of biological sampling techniques, analytical methods for measurement of drug (and metabolites) concentration in biological samples and data collection and evaluation.

Several relevant terms: Clinical Pharmacokinetics is defined as the application of pharmacokinetic principles in the safe and effective management of individual patient. Population Pharmacokinetics is defined as the study of pharmacokinetic differences of drugs in various population groups. Toxicokinetics is defined as the application of pharmacokinetic principles to the design, conduct and interpretation of drug safety evaluation studies.

Plasma Drug Concentration Time Profile A direct relationship exists between the concentration of drug at the biophase (site of action) and the concentration of drug in plasma. Two categories of parameters can be evaluated from a plasma concentration time profile Pharmacokinetic parameters, and Pharmacodynamic parameters. A typical plasma drug concentration time curve obtained after a single oral dose of a drug and showing various pharmacokinetic and pharmacodynamic parameters is depicted in figure. Such a profile can be obtained by measuring concentration of drug in plasma samples taken at various intervals of time after administration of a dosage form and plotting the concentration of drug in plasma (Y axis) versus the corresponding time at which the plasma sample was collected(x axis).

Plasma Drug Concentration time Profile Peak plasma conc. Cmax (absorption rate=elimination rate) Plasma Drug Concentration Onset of action Intensity of action Duration of action Area under the curve (AUC) Toxic level Termination Of action Subtherapeutic level Maximum Safe Conc. (MSC) Therapeutic range Minimum effective conc.(mec) Onset time Elimination Phase tmax Time for peak plasma conc. Time

Pharmacokinetic Parameters The three important pharmacokinetic parameters that describe the plasma level time curve and useful in assessing the bioavailability of a drug from its formulation are 1. Peak Plasma concentration (Cmax): The point of maximum concentration of drug in plasma is called as the peak and the concentration of drug at peak is known as peak plasma concentration. It is also called as peak height concentration and maximum drug concentration. Cmax is expressed in mcg/ml.

The peak level depends upon Dose administered Rate of absorption, and Rate of elimination. The peak represents the point of time when absorption rate equals elimination rate of drug. The portion of curve to the left of peak represents absorption phase i.e. when the rate of absorption is greater than the rate of elimination. The section of curve to the right of peak generally represents elimination phase i.e. when the rate of elimination exceeds rate of absorption. Peak concentration is often related to the intensity of pharmacological response and should ideally be above minimum effective concentration (MEC) but less than the maximum safe concentration (MSC).

2. Time of Peak Concentration (tmax): The time for drug to reach peak concentration in plasma (after extravascular administration) is called as the time of peak concentration. It is expressed in hours and is useful in estimating the rate of absorption. Onset time and onset of action are dependent upon tmax. The parameter is of particular importance in assessing the efficacy of drug used to treat acute conditions like pain and insomnia which can be treated by a single dose.

3. Area Under the Curve(AUC): It represents the total integrated area under the plasma level time profile and expresses the total amount of drug that comes into the systemic circulation after its administration. AUC is expressed in mcg/ml * hours. It is the most important parameter in evaluating the bioavailability of a drug from its dosage form as it represents the extent of absorption. AUC is also important for drugs that are administered repetitively for the treatment of chronic conditions like asthma or epilepsy.

Pharmacodynamic Parameters The various Pharmacodynamic parameters are 1. Minimum Effective Concentration (MEC): It is defined as the minimum concentration of drug in plasma required to produce the therapeutic effect. It reflects the minimum concentration of drug at the receptor site to elicit the desired pharmacological response. The concentration of drug below MEC is said to be in the sub therapeutic level. In case of antibiotics, the term minimum inhibitory concentration (MIC) is used. It describes the minimum concentration of antibiotic in plasma required to kill or inhibit the growth of micro organisms.

2. Maximum Safe Concentration (MSC): Also called as minimum toxic concentration (MTC) It is the concentration of drug in plasma above which adverse or unwanted effects are precipitated. Concentration of drug abovemscissaidtobeinthetoxic level. 3. Onset of Action: The beginning of pharmacological response is called as onset of action. It occurs when the plasma drug concentration just exceeds the required MEC. 4. Onset Time: It is the time required for the drug to start producing pharmacological response. It corresponds to the time for the plasma concentration to reach MEC after administration of drug.

5. Duration of Action: The time period for which the plasma concentration of drug remains above the MEC level is called as duration of drug action. It is also defined as the difference between onset time and time for the drug to decline back to MEC. 6. Intensity of Action : It is the maximum pharmacological response produced by the peak plasma concentration of drug. It is also called as peak response.

7. Therapeutic Range : The drug concentration between MEC represents the therapeutic range. It is Also known as therapeutic window. and MSC 8. Therapeutic Index : The ratio of MSC to MEC is called as therapeutic index. It is also defined as the ratio of dose required to produce toxic or lethal effects to dose required to produce therapeutic effect.

Reference Brahmankar DM, Jaiswal SB, Pharmacokinetics: Basic Considerations In Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, Second edition, 2009, pp: 235 39